According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “
Separately, ValuEngine raised Vaccinex from a hold rating to a buy rating in a report on Thursday, October 10th.
Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.07). The business had revenue of $0.03 million for the quarter. Vaccinex had a negative net margin of 6,349.13% and a negative return on equity of 306.27%. On average, sell-side analysts expect that Vaccinex will post -2.6 EPS for the current year.
In other news, insider Maurice Zauderer acquired 183,824 shares of Vaccinex stock in a transaction that occurred on Tuesday, July 30th. The stock was bought at an average price of $4.08 per share, for a total transaction of $750,001.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Albert Friedberg acquired 1,838,235 shares of Vaccinex stock in a transaction that occurred on Tuesday, July 30th. The shares were purchased at an average price of $4.08 per share, with a total value of $7,499,998.80. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 2,023,111 shares of company stock valued at $8,254,198. 69.90% of the stock is owned by company insiders.
An institutional investor recently bought a new position in Vaccinex stock. Creative Planning acquired a new stake in shares of Vaccinex Inc (NASDAQ:VCNX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $55,000. Creative Planning owned about 0.09% of Vaccinex as of its most recent filing with the Securities and Exchange Commission (SEC). 1.30% of the stock is owned by institutional investors and hedge funds.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
See Also: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.